08 Aug2019

Corindus Vascular Robotics Announces Definitive Agreement to be Acquired by Siemens Healthineers

Written by 2020HCP.com. Posted in News

WALTHAM, Mass., — August 8, 2019 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion.

26 Feb2019

Hillel Bachrach Serves as Moderator at MIT Sloan School of Management Innovation Panel

Written by 2020HCP.com. Posted in News

Big Data, Digitalization, and Disruption: How are the headline trends of new technology and therapeutic innovation changing how we address today’s biggest healthcare challenges?

HITInfrastructure.com covers the event:

Digital Health Technology Needs to Fit into the Clinical Workflow

The biggest question when it come to digital health technology is not getting “new, cool stuff” into the hospital, but how can it fit seamlessly into the existing clinical workflow, observed Jaydeo Kinikar, head of marketing and business development at Philips Connected Care Sensing.

11 Feb2019

3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

Written by 2020HCP.com. Posted in News

SHENYANG, China and BOSTON Mass., February 11, 2019 /PRNewswire/ — 3SBio Inc. (“3SBio”) (HKEX:1530) and Verseau Therapeutics, Inc. (“Verseau”) announced today a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. Verseau’s proprietary drug discovery platform generates first-in-class macrophage checkpoint modulators (MCMs) to benefit patients with cancer, immune and inflammatory diseases.
06 Feb2019

Omron Healthcare and physIQ Partner to Transform Cardiovascular Patient Care

Written by 2020HCP.com. Posted in News

  • Omron HeartGuide™, the first wearable blood pressure device, will integrate with physIQ’s pinpointIQ® analytics platform to indicate a potential health risk
  • This combined solution is being deployed to help manage recently-discharged, at-risk patients
  • The goal is to provide clinicians with physiological insight to proactively address potential clinical deterioration
CHICAGO, February 6, 2019 – Omron Healthcare, Inc. and physIQ Inc. today announced a collaboration to integrate Omron’s innovative FDA-cleared device, HeartGuide™, the first wearable blood pressure monitor into the pinpointIQ® platform to monitor at-risk patients in an outpatient setting. The strategic collaboration aims to generate actionable clinical information for at-risk patients in an outpatient environment by leveraging the complementary technologies of each company. Omron is the global leader in personal heart health and wellness technology and physIQ is a pioneer in FDA-cleared Artificial Intelligence physiology analytics.

Latest News